U.S. Markets open in 49 mins
  • S&P Futures

    4,704.00
    +2.50 (+0.05%)
     
  • Dow Futures

    35,830.00
    +19.00 (+0.05%)
     
  • Nasdaq Futures

    16,494.75
    +13.50 (+0.08%)
     
  • Russell 2000 Futures

    2,365.40
    +1.20 (+0.05%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    58,011.82
    +949.46 (+1.66%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Dalrada Corporation’s Pala Diagnostics Free COVID-19 Point-of-care Tests Proved Compliance for Nearly 3,000 Outdoor Festival Attendees

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, September 16, 2021--(BUSINESS WIRE)--Dalrada Corporation (OTCQB: DFCO, "Dalrada") is excited to share information on the Company’s community outreach efforts that support free, on-site COVID-19 point-of-care tests at in-person events. Pala Diagnostics, LLC ("Pala Diagnostics"), a joint venture between Dalrada Health and Vivera Pharmaceuticals, Inc., is a fully operational national laboratory that processes point-of-care, EUA approved, rapid antigen testing, and lab-based PCR testing for COVID-19.

Pala Diagnostics performed both RT-PCR Tests and FDA-authorized Antigen Tests throughout the three-day Boise Pride Festival and Parade. Nearly 3,000 point-of-care tests were administered and processed utilizing Vivera’s exclusive proprietary software LabPort.

To ensure the health and safety of its guests, event coordinators required all attendees, volunteers, performers, and staff to show proof of COVID-19 immunization or a negative PCR or antigen test. All recipients of Pala Diagnostics’ HIPAA compliant test results received a text message to retrieve evidence of COVID-19 testing. All who provided valid proof received an event health check wristband before entry into the festival.

Brian Bonar, Chairman and CEO of Dalrada, states, "The collaboration between Boise Pride and Pala Diagnostics is a prime example of successfully implementing safety protocols to restore attendance at large public events. Dalrada looks forward to engaging with the community to facilitate safe social congregation, according to recommended public health policy."

Pala Diagnostics is a CLIA-certified state-of-the-art diagnostic laboratory with mobile concierge services for businesses and institutions to facilitate safer back-to-work and back-to-school protocols. Pala Diagnostics provides complete on-site testing services for high-volume settings, rapid results within 24-hours for point-of-care PCR testing, and a range of life science testing, including SARS-CoV-2.

Dalrada continuously builds on its core practices of engineering, life sciences, and technology while operating under the tenet of bringing innovative products and services to a complex new world. As consumers, businesses, and governments look for some type of normalcy, Dalrada’s subsidiaries are responding with alternative solutions that are affordable, available, accessible, and impactful.

For more information on Dalrada and its subsidiaries, visit www.dalrada.com.

About Dalrada (DFCO)

With perseverance, valor, dedication, and vision, Dalrada Corporation is dedicated to tackling worldwide challenges of today and tomorrow.

Dalrada is a global company that operates under the tenet of creating impactful innovations that matter for the world. The Company works continually to produce disruptive solutions that bridge the gap of accessibility and accelerate positive change for current and future generations.

Established in 1982, the Company has since grown its footprint to include the business divisions: Dalrada Health, Dalrada Precision, and Dalrada Technologies. Each of Dalrada’s subsidiaries actively produces affordable and accessible world-class solutions to global problems. For more information, please visit www.dalrada.com.

Disclaimer

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005826/en/

Contacts

Denise Mahaffey
858.283.1253
inquiries@dalrada.com